Comparison of in vivo outcome following transfusion of dynamic light scattering-screened versus unscreened platelets

Completed

• Conditions: Platelet transfusion; hematological malignancy; Haematological Disorders; Other diseases of blood and blood-forming organs

• Registration Number: ISRCTN01292427
• Lead Sponsor: Vancouver Coastal Health (Canada)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-07-16
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

We propose to enrol 200 leukemia and bone marrow transplant inpatients, as frequent recipients of prophylactic and therapeutic platelet transfusions.
All patients >18 years of age with hematologic malignancies on the leukemia and bone marrow transplant ward VGH (T15), undergoing stem cell transplantation or chemotherapy, and expected to require at least one platelet transfusion will be considered for enrolment.

Exclusion Criteria

1. Patients who have received platelet transfusion (outside the CoDIVO study) within the past two weeks
2. Patients known to require Human Leukocyte Antigen (HLA) matched platelet support will be ineligible, due to TML's inability to guarantee availability of HLA matched platelets with TL score >15 in experimental arm
3. Patients with documented splenomegaly will be excluded, because an enlarged spleen causes enhanced platelet removal
4. Unable to provide informed consent
5. Unreliable availability of appropriate English translator (Daily bleeding scores required)
6. Pregnancy
7. Major surgery within the previous two weeks
8. Acute promyelocytic leukemia
9. Idiopathic or Thrombotic thrombocytopenic purpura or Hemolytic Uremic Syndrome

Study & Design

• Study Type: Interventional
• Study Design: Not specified